Creative Biolabs is a biotechnology company providing antibody discovery and engineering services for research and therapeutic development. It supports global pharmaceutical and academic customers.
AI-driven drug discovery attracts major investment and partnerships: Galux closes $29M Series B, LG Chem partners with LabGenius on cancer antibodies, Cheiron raises $8M seed, and Peptris secures $7.7M. Galux also teams with AimedBio on BBB-crossing proteins.
Creative Biolabs has expanded its preclinical research capabilities with an upgraded rodent behavioral profiling platform for CNS drug discovery and enhanced circRNA and nucleic acid analysis platforms for gene therapy development.
Researchers unveil pancreatic-targeted lipid nanoparticles using capsule filtration mechanisms, while a contract research organization expands lipid-based vector development services for organ-selective mRNA delivery.
